ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Articles tagged "Adverse effects"

  • 2019 American Transplant Congress

    Elevated Visceral Adiposity is Associated with Post-Liver Transplant Mortality and Poorly Correlates with BMI in a Prospective Cohort Study

    R. Sharma, R. Rosenblatt, R. Knotts, J. Pisa, E. Verna

    Division of Liver Diseases and Transplantation, Columbia Univerisity Medical Center, New York, NY

    *Purpose: Obesity is increasingly common in end-stage-liver disease (ESLD). While obesity adversely affects outcomes, whether abnormalities in specific adipose tissue (AT) compartments lead to increased…
  • 2019 American Transplant Congress

    Significant Implications of Prior Transplantation on Treatment and Outcomes of Patients Suffering from Traumatic Brain Injury

    L. Mugge, W. Qu, C. Gallagher, A. Caras, N. Henkel, O. Ekwenna, J. Ortiz

    The University of Toledo Medical Center, Toledo, OH

    *Purpose: Recent events in the media and sporting industry highlight traumatic brain injury (TBI) as a major health concern, having implications in many areas of…
  • 2019 American Transplant Congress

    Microfluidic Study Analyzing the Effect of Immediate-Release and Extended-Release Tacrolimus on Islet Function

    P. West-Thielke1, J. Oberholzer2, Y. Wang3

    1University of Illinois, Chicago, IL, 2University of Virgina, Charlottesville, VA, 3University of Virginia, Charlottesville, VA

    *Purpose: The purpose of this analysis was to quantify the impact of 2 tacrolimus pharmacokinetic profiles on functional changes within human islet cells using a…
  • 2019 American Transplant Congress

    Evaluating Potentially Inappropriate Prescribing in Older Kidney Transplant Recipients

    L. DeVietro1, B. Richardson2, E. A. Cohen3, A. H. Toledo4, E. Marin5, K. R. Szempruch6

    1University of St. Joseph School of Pharmacy, Hartford, CT, 2University of North Carolina Eshelman School of Pharmacy, Chapel Hill, NC, 3Pharmacy, Yale New Haven Hospital, New Haven, CT, 4Surgery-Transplant, University of North Carolina Medical Center, Chapel Hill, NC, 5Nephrology, Yale New Haven Hospital, New Haven, CT, 6Pharmacy, University of North Carolina Medical Center, Chapel Hill, NC

    *Purpose: While the Beers criteria (BC) and STOPP criteria (SC) have been validated in several patient populations to reduce medication use leading to adverse drug…
  • 2019 American Transplant Congress

    Adverse Effect Differences between Tacrolimus-IR and LCP-Tacrolimus

    J. Hagopian1, C. Carthon1, S. January1, A. Gharabagi2, R. Delos Santos3, T. Horwedel4

    1Barnes-Jewish Hospital, Saint Louis, MO, 2St. Louis College of Pharmacy, Saint Louis, MO, 3Washington Universidy, Saint Louis, MO, 4Veloxis Pharmaceuticals, Inc, Cary, NC

    *Purpose: Extended-release tacrolimus (Envarsus XR®, LCP-Tac) was approved in 2015 as conversion from tacrolimus immediate-release (Tac-IR) as part of the maintenance immunosuppression regiment post-kidney transplant.…
  • 2019 American Transplant Congress

    Early Readmission After Renal Transplant As A Valuable Quality Measure

    S. Kim1, A. Osband1, B. Merhi2, G. Bayliss2, R. Gohh2, P. Morrissey1

    1Surgery, Rhode Island Hospital, Providence, RI, 2Nephrology, Rhode Island Hospital, Providence, RI

    *Purpose: Patient and graft survival have been criticized as imprecise measures of transplant program quality. Thirty-day (30d) readmission rates, available nationally and attainable locally, may…
  • 2019 American Transplant Congress

    Functional Measures of Frailty and Not Sarcopenia Predict Mortality in a Prospective Cohort of Liver Transplant Candidates

    R. Sharma, R. Rosenblatt, R. Knotts, J. Pisa, E. Verna

    Division of Liver Diseases and Transplantation, Columbia Univeristy Medical Center, New York, NY

    *Purpose: Sarcopenia determined by single slice measures of abdominal imaging have been correlated with liver transplant (LT) outcomes. However, in end-stage liver disease (ESLD), these…
  • 2019 American Transplant Congress

    mTOR Inhibitors Associated with Higher Cardiovascular Adverse Events – A Large Population Database Analysis

    V. N. Nguyen1, R. Abagyan2, S. Tsunoda2

    1Pharmacy, UC San Diego Health, San Diego, CA, 2Skaggs School of Pharmacy and Pharmaceutical Sciences, San Diego, CA

    *Purpose: Our study aimed to compare the adverse events (AEs) of tacrolimus to mammalian target of rapamycin (mTOR) inhibitors in solid organ transplant patients.*Methods: Our…
  • 2019 American Transplant Congress

    Pneumocystis Prophylaxis in Solid Organ Transplant Recipients at Two Large Transplant Centers from 2015-2016: Why Not Trimethoprim-Sulfamethoxazole?

    J. M. Lum1, V. Athans2, I. Echenique3, C. E. Koval1

    1Infectious Diseases, Cleveland Clinic Floundation, Cleveland, OH, 2Infectious Diseases, University of Pennsylvania, Philadelphia, PA, 3Infectious Diseases, Cleveland Clinic Florida, Weston, FL

    *Purpose: Trimethoprim-sulfamethoxazole (T/S) is the drug of choice for Pneumocystis jirovecii pneumonia (PJP) prophylaxis (ppx) after solid organ transplant (SOT). Perceived side effects may lead…
  • 2019 American Transplant Congress

    Renal Function between Tenofovir and Entecavir in Post-Liver Transplanted Hepatitis B Patients

    S. Kim, J. Kim, S. Lee, J. Rhu, Y. Chung, S. Kim, J. Joh, S. Lee, G. Choi, J. Park, S. Lee, K. Lee

    Transplantation, Samsung Medical Center, Seoul, Korea, Republic of

    *Purpose: Tenofovir, Nucleotide analogue polymerase inhibitor is already accepted as effective and tolerable drug for treatment of hepatitis B virus (HBV) as much as entecavir.…
  • « Previous Page
  • 1
  • …
  • 9
  • 10
  • 11
  • 12
  • 13
  • …
  • 18
  • Next Page »

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences